Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMINE: Lebrikizumab in Nummular Eczema
NCT07542483Phase 3Recruiting
- Sponsor
- Almirall
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lebrikizumab in nummular eczema (4 arms), sponsored by Almirall. Primary endpoint: Investigator Global Assessment Score of 0 or 1 and a >=2-point Reduction at 24 weeks. Started Apr 2026; status: recruiting.
02
Drugs
lebrikizumab
03
Conditions
nummular eczema
Beyond the preview
Go deeper on NCT07542483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542483.